Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Conditions

• Accelerated Phase of Disease
• Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
• Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
• Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
• Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
• Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
• Blastic Phase
• Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Chronic Myelomonocytic Leukemia
• de Novo Myelodysplastic Syndrome
• Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
• Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
• Previously Treated Myelodysplastic Syndrome
• Primary Myelofibrosis
• Recurrent Adult Acute Lymphoblastic Leukemia
• Recurrent Adult Acute Myeloid Leukemia
• Recurrent Disease
• Secondary Acute Myeloid Leukemia
• Secondary Myelodysplastic Syndrome

Interventions

• DRUG: Belinostat
• DRUG: Azacitidine
• OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)